IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules
IBCSG 59-19
Phase 3 small_molecule active
Quick answer
IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules for Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer. is a Phase 3 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active